Insider Trading February 24, 2026

Honeywell Director Disposes $1.4M in Stock; Exercises Options in Same Session

Grace Lieblein sold 5,857 shares and exercised options for 7,777 shares as Honeywell navigates valuation questions and a revised Johnson Matthey deal

By Leila Farooq HON
Honeywell Director Disposes $1.4M in Stock; Exercises Options in Same Session
HON

Honeywell International director Grace Lieblein sold 5,857 shares of common stock on February 23, 2026, for about $1.4 million and exercised options to acquire 7,777 shares the same day. The transactions occurred near the stock's 52-week high and come as the company faces valuation scrutiny and completes strategic moves including a reduced-price acquisition of Johnson Matthey's Catalyst Technologies business and reported impairment charges in its Industrial Automation segment.

Key Points

  • Grace Lieblein sold 5,857 Honeywell shares on February 23, 2026, at $243.73 per share, totaling about $1.4 million.
  • On the same day, Lieblein exercised options to acquire 7,777 Honeywell shares at strike prices between $117.58 and $163.47, valued at $1,058,696.
  • Honeywell reported Q4 2025 EPS of $2.59 and revenue of $10.1 billion, declared a $1.19 quarterly dividend payable March 13, 2026, and disclosed impairment charges totaling $471 million across Industrial Automation and assets held for sale.

Grace Lieblein, who serves on the board of Honeywell International Inc, executed an open-market sale of 5,857 shares of Honeywell common stock on February 23, 2026. The shares were sold at $243.73 each, producing proceeds of roughly $1.4 million. That sale price sat just under the company stock's 52-week peak of $246.

Also on February 23, Lieblein exercised stock options to acquire a total of 7,777 Honeywell shares. Those option exercises carried prices ranging from $117.58 to $163.47, representing a combined value of $1,058,696 based on the exercise prices disclosed.

The transactions took place against the backdrop of valuation commentary on Honeywell. The industrial conglomerate is valued at approximately $155 billion and trades at a price-to-earnings ratio of 35.45. Analysis from InvestingPro cited in company materials indicates the stock is trading above its Fair Value and lists Honeywell among companies flagged as Most Overvalued.


Beyond insider activity, Honeywell announced a revised purchase agreement to acquire Johnson Matthey's Catalyst Technologies division for

The revised purchase price for the Catalyst Technologies unit is

Honeywell said the deadline to complete the acquisition has been extended to July 21, 2026, and may be further prolonged to August 21, 2026, pending regulatory approvals. Johnson Matthey has disclosed plans to return to shareholders from the sale proceeds, including an

In its reporting for the fourth quarter of 2025, Honeywell posted earnings per share of $2.59 and revenue of $10.1 billion, both of which exceeded analysts' expectations. The company also declared a quarterly cash dividend of $1.19 per share, with the payment scheduled for March 13, 2026.

Honeywell disclosed additional impairment charges within its Industrial Automation segment totaling $436 million, alongside a $35 million impairment charge related to assets held for sale. These charges were listed in the company's disclosures and reflect adjustments in that business area.


Taken together, the director's share sale and option exercises occurred amid active corporate developments at Honeywell, including strategic transactions, updated financial results, and segment-level impairment recognition.

Risks

  • Valuation risk - InvestingPro analysis places Honeywell above its Fair Value and on a Most Overvalued list, which may influence investor sentiment in the industrials sector.
  • Regulatory and deal completion risk - The acquisition of Johnson Matthey's Catalyst Technologies division has a revised purchase price and extended deadlines to July 21, 2026, with a possible further extension to August 21, 2026, making completion contingent on regulatory approvals.
  • Operational and financial performance risk - Additional impairment charges of $436 million in Industrial Automation and $35 million on assets held for sale indicate potential challenges within that business segment.

More from Insider Trading

ImmunityBio Director Sells $250,000 in Stock as Company Posts Strong ANKTIVA Revenue Gains Feb 24, 2026 Palantir CEO Disposes $65.9M of Class A Shares, Converts Class B Stock Amid Corporate Momentum Feb 24, 2026 Palantir Director Sells $43.7M in Class A Shares as Stock Trades Below Peak Levels Feb 24, 2026 ImmunityBio Director Executes $1.78M Stock Sales as ANKTIVA Revenue Accelerates Feb 24, 2026 KalVista CFO Disposes $27,506 in Stock as Company Posts Strong EKTERLY Launch Metrics Feb 24, 2026